Dupixent (dupilumab)
pCPA File Number:
23227
Negotiation Status:
Under consideration for negotiation
Indication(s):
Severe chronic rhinosinusitis with nasal polyps
Sponsor/Manufacturer:
Sanofi-Aventis Canada Inc.
CDA-AMC Project Number:
SR0878-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable